# Biotech M&A

Latest news and articles about Biotech M&A

Total: 2 articles found

Intricate abstract representation of a cellular structure with a glowing core on a white background.

AbbVie’s $11 Billion Gambit: Securing the Future of Immunology Beyond the Humira Cliff

AbbVie has entered an agreement to acquire Apogee Therapeutics for $10.9 billion to bolster its immunology portfolio. The deal focuses on zumilokibart, a next-generation treatment for inflammatory diseases that offers significantly less frequent dosing than current market leaders.

NeTe2026年6月22日 18:38

#AbbVie#Apogee Therapeutics#Immunology

Close-up of Versa HD radiotherapy machine in a clinical setting.

Business

Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss

Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.

NeTe2026年4月20日 17:58

#Eli Lilly#Kelonia Therapeutics#Oncology